Cheresh和同事们长期以来致力于研发一类新的RAF抑制剂。研究人员设想开发一类新药物主要是通过改变目标酶的形状来使其失活。由于不与酶的活性位点结合，因而克服了当前药物存在的一些缺陷。在新研究中，Cheresh等开发了一种特异性靶向增殖细胞RAF的药物KG5。

Hood, J. D. & Cheresh, D. A. Role of integrins in cell invasion and migration. Nature Rev. Cancer 2 , 91–100 (2002) Article Google Scholar ...

Relative to existing gene signatures, the STRESS signature better predicted not only whether cells would later develop into ...

David A. Cheresh, Ph.D., professor of pathology at the University of California, San Diego School of Medicine and associate director for translational research at the Moores UCSD Cancer Center ...

Cheresh and an international team of scientists found cilengitide is effective in patient-derived tumor cells of a defined subpopulation with proneural and classical glioblastoma subtypes.

Now, Cheresh and colleagues have reported data in the Journal of Biological Chemistry that help reconcile these findings, describing how fully adherent cells undergo apoptosis when their integrins ...

David A. Cheresh, PhD, professor of pathology at the University of California, San Diego School of Medicine and associate director for translational research at the Moores UCSD Cancer Center, has been ...

Articles by David Cheresh. Opinion: Stopping the Cancer Cells that Thrive on Chemotherapy. Chengsheng Wu, David Cheresh, Sara Weis and The Conversation | | 5 min read. Research into how pancreatic ...

Cheresh said that newly forming tumors, still too small to be detected, depend on a fresh supply of blood. With doxorubicin rendering them unable to form blood vessels, the tumors didn't grow.

The study was led by David Cheresh, PhD, Distinguished Professor and vice chair of the Department of Pathology at UC San Diego School of Medicine and a member of the UC San Diego Moores Cancer Center.

Using the nanoparticles, researchers found that a much smaller dose of the drug was effective, and it wasn't accompanied by "the collateral damage of weight loss or other outward signs of toxicity in ...